Crosstalk between TGF-β Signaling and miRNAs in Breast Cancer Metastasis|
The reviewers focus on the interaction between miRNAs and transforming growth factor-β (TGF-β) in breast cancer metastasis through modulating invasion-metastasis-related factors, including epithelial-to-mesenchymal transition, cancer stem cells, matrix metalloproteinase (MMP), tissue inhibitors of MMPs, cell adhesion molecules, and tumor microenvironment. [Tumour Biol] Abstract
Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Avelas Biosciences Announces Positive Interim Phase Ib Results and Advances to Dose Expansion Stage|
Avelas Biosciences, Inc. announced positive interim results from a Phase Ib trial of its AVB-620 surgical marker in women with primary, non-recurrent breast cancer undergoing surgery. [Avelas Biosciences, Inc.] Press Release
Concure Oncology® Launches One-Time, One-Day Radiation Treatment for Early-Stage Breast Cancer
Concure Oncology/Breast Microseed, Inc. announces the launch of its one-time, one-hour radiation treatment option for early-stage breast cancer. Breast Microseed Treatment makes a quicker return to normal activity possible for post-lumpectomy patients by offering a simple, more convenient outpatient procedure. [Concure Oncology/Breast Microseed, Inc. (2016 PR Newswire Association LLC)] Press Release
Innocrin Pharmaceuticals, Inc. Begins Phase II Study of Seviteronel in Women with Estrogen Receptor-Positive or Triple-Negative Breast Cancer
Innocrin Pharmaceuticals, Inc. announced that they have started dosing in a Phase II study of women with estrogen receptor-positive or triple-negative breast cancer. The Phase I portion of the seviteronel study has completed and a once-daily dose was selected for advancement into Phase II development. [Innocrin Pharmaceuticals, Inc.] Press Release
From our sponsor:
Discover how to reduce variability in primary neuron cultures with NeuroCult™ SM. Watch the webinar.